181 related articles for article (PubMed ID: 9635697)
1. The treatment of nonpalpable PSA-detected adenocarcinoma of the prostate with 3-dimensional conformal radiation therapy.
Horwitz EM; Hanlon AL; Pinover WH; Hanks GE
Int J Radiat Oncol Biol Phys; 1998 Jun; 41(3):519-23. PubMed ID: 9635697
[TBL] [Abstract][Full Text] [Related]
2. Dose escalation with 3D conformal treatment: five year outcomes, treatment optimization, and future directions.
Hanks GE; Hanlon AL; Schultheiss TE; Pinover WH; Movsas B; Epstein BE; Hunt MA
Int J Radiat Oncol Biol Phys; 1998 Jun; 41(3):501-10. PubMed ID: 9635695
[TBL] [Abstract][Full Text] [Related]
3. Dose response in prostate cancer with 8-12 years' follow-up.
Hanks GE; Hanlon AL; Epstein B; Horwitz EM
Int J Radiat Oncol Biol Phys; 2002 Oct; 54(2):427-35. PubMed ID: 12243818
[TBL] [Abstract][Full Text] [Related]
4. Perineural invasion and Gleason 7-10 tumors predict increased failure in prostate cancer patients with pretreatment PSA <10 ng/ml treated with conformal external beam radiation therapy.
Anderson PR; Hanlon AL; Patchefsky A; Al-Saleem T; Hanks GE
Int J Radiat Oncol Biol Phys; 1998 Jul; 41(5):1087-92. PubMed ID: 9719119
[TBL] [Abstract][Full Text] [Related]
5. Results of 3D conformal radiotherapy in the treatment of localized prostate cancer.
Fukunaga-Johnson N; Sandler HM; McLaughlin PW; Strawderman MS; Grijalva KH; Kish KE; Lichter AS
Int J Radiat Oncol Biol Phys; 1997 May; 38(2):311-7. PubMed ID: 9226317
[TBL] [Abstract][Full Text] [Related]
6. Outcome and predictive factors for patients with Gleason score 7 prostate carcinoma treated with three-dimensional conformal external beam radiation therapy.
Anderson PR; Hanlon AL; Horwitz E; Pinover W; Hanks GE
Cancer; 2000 Dec; 89(12):2565-9. PubMed ID: 11135217
[TBL] [Abstract][Full Text] [Related]
7. Evidence of increased failure in the treatment of prostate carcinoma patients who have perineural invasion treated with three-dimensional conformal radiation therapy.
Bonin SR; Hanlon AL; Lee WR; Movsas B; al-Saleem TI; Hanks GE
Cancer; 1997 Jan; 79(1):75-80. PubMed ID: 8988729
[TBL] [Abstract][Full Text] [Related]
8. Relationship between prostate volume, prostate-specific antigen nadir, and biochemical control.
Kaminski JM; Hanlon AL; Horwitz EM; Pinover WH; Mitra RK; Hanks GE
Int J Radiat Oncol Biol Phys; 2002 Mar; 52(4):888-92. PubMed ID: 11958880
[TBL] [Abstract][Full Text] [Related]
9. Defining the optimal radiation dose with three-dimensional conformal radiation therapy for patients with nonmetastatic prostate carcinoma by using recursive partitioning techniques.
Horwitz EM; Hanlon AL; Pinover WH; Anderson PR; Hanks GE
Cancer; 2001 Sep; 92(5):1281-7. PubMed ID: 11571744
[TBL] [Abstract][Full Text] [Related]
10. Early stage prostate cancer treated with radiation therapy: stratifying an intermediate risk group.
Lattanzi JP; Hanlon AL; Hanks GE
Int J Radiat Oncol Biol Phys; 1997 Jun; 38(3):569-73. PubMed ID: 9231681
[TBL] [Abstract][Full Text] [Related]
11. Prostate cancer patient subsets showing improved bNED control with adjuvant androgen deprivation.
Anderson PR; Hanlon AL; Movsas B; Hanks GE
Int J Radiat Oncol Biol Phys; 1997 Dec; 39(5):1025-30. PubMed ID: 9392540
[TBL] [Abstract][Full Text] [Related]
12. External beam radiotherapy dose response characteristics of 1127 men with prostate cancer treated in the PSA era.
Pollack A; Smith LG; von Eschenbach AC
Int J Radiat Oncol Biol Phys; 2000 Sep; 48(2):507-12. PubMed ID: 10974469
[TBL] [Abstract][Full Text] [Related]
13. Defining the appropriate radiation dose for pretreatment PSA < or = 10 ng/mL prostate cancer.
Pinover WH; Hanlon AL; Horwitz EM; Hanks GE
Int J Radiat Oncol Biol Phys; 2000 Jun; 47(3):649-54. PubMed ID: 10837947
[TBL] [Abstract][Full Text] [Related]
14. Optimization of conformal radiation treatment of prostate cancer: report of a dose escalation study.
Hanks GE; Schultheiss TE; Hanlon AL; Hunt M; Lee WR; Epstein BE; Coia LR
Int J Radiat Oncol Biol Phys; 1997 Feb; 37(3):543-50. PubMed ID: 9112451
[TBL] [Abstract][Full Text] [Related]
15. Association of percent positive prostate biopsies and perineural invasion with biochemical outcome after external beam radiotherapy for localized prostate cancer.
Wong WW; Schild SE; Vora SA; Halyard MY
Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):24-9. PubMed ID: 15337536
[TBL] [Abstract][Full Text] [Related]
16. [Biochemical control after conformal, 3 dimensional radiotherapy of prostatic carcinoma].
Geinitz H; Zimmermann F; von Wedel E; Thamm R; Busch R; Feldmann HJ; Molls M
Strahlenther Onkol; 2002 Jul; 178(7):369-77. PubMed ID: 12163991
[TBL] [Abstract][Full Text] [Related]
17. Postradiotherapy PSA nadirs fail to support dose escalation study in patients with pretreatment PSA values < 10 ng/ml.
Herold D; Hanks G; Movsas B; Hanlon A
Radiat Oncol Investig; 1997; 5(1):15-9. PubMed ID: 9303052
[TBL] [Abstract][Full Text] [Related]
18. Is there a role for short-term hormone use in the treatment of nonmetastatic prostate cancer?
Horwitz EM; Hanlon AL; Pinover WH; Hanks GE
Radiat Oncol Investig; 1999; 7(4):249-59. PubMed ID: 10492166
[TBL] [Abstract][Full Text] [Related]
19. Outcome evaluation of the 1997 American Joint Committee on Cancer staging system for prostate carcinoma treated by radiation therapy.
Iyer RV; Hanlon AL; Pinover WH; Hanks GE
Cancer; 1999 Apr; 85(8):1816-21. PubMed ID: 10223577
[TBL] [Abstract][Full Text] [Related]
20. Long-term outcome after elective irradiation of the pelvic lymphatics and local dose escalation using high-dose-rate brachytherapy for locally advanced prostate cancer.
Galalae RM; Kovács G; Schultze J; Loch T; Rzehak P; Wilhelm R; Bertermann H; Buschbeck B; Kohr P; Kimmig B
Int J Radiat Oncol Biol Phys; 2002 Jan; 52(1):81-90. PubMed ID: 11777625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
